HY01.01LB VRC01 antibody prevention of HIVOral Abstract SessionClinical trial results
HY01.02LB Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084Oral Abstract SessionClinical trial results
OA01.01 Evaluation of the kinetics of systemic distribution of IV injected monoclonal antibodies modified to alter host mediated Fc interaction in the rhesus macaque modelOral Abstract SessionBroadly neutralizing antibodies
OA01.02 Monoclonal antibodies with ultra-long CDRH3 derived from vaccinated cows show exceptional neutralisation potency and breadth that is retained after Fc engineeringOral Abstract SessionHumoral immunity
OA01.03 Fc?RIIa rs10800309 polymorphism is a HLA-B57 and HLA-B27 independent predictor of HIV controlOral Abstract SessionHumoral immunity
OA01.04 Serum IgA inhibits HIV-specific broadly neutralising antibody Fc functionsOral Abstract SessionBroadly neutralizing antibodies
OA01.05LB Opening the HIV-1 envelope for neutralization and antibody-dependent cellular cytotoxicityOral Abstract SessionTherapeutic vaccines, viral reservoirs and eradication/remission
OA02.01 Profiling the HIV epidemic with recency of infection instead of recency of diagnosis: 2 years of experience in North Carolina, USAOral Abstract SessionEpidemiology of HIV
OA02.02 Correlates of high HIV transmission areas in a generalized hyperendemic setting: findings from a national survey in EswatiniOral Abstract SessionTreatment as prevention
OA02.03 Progress toward HIV elimination goals: trends in and projections of treatment as prevention strategy in 38 African countriesOral Abstract SessionTreatment as prevention